Company news
Benitec Biopharma Inc. (NASDAQ:BNTC) news
Every Benitec Biopharma Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Benitec Biopharma to Present at the JMP Securities Life Sciences Conference
May 8, 2023
Benitec Biopharma to Present at the OPMD International Conference
May 8, 2023
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
February 13, 2023
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
January 23, 2023
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
November 10, 2022
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
September 16, 2022
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
September 12, 2022
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
September 2, 2022
Benitec Biopharma Releases Q3 2022 Financial Results
May 16, 2022
Benitec Biopharma Discloses Q2 2022 Financial Results
February 14, 2022
Benitec Biopharma Discloses Q1 2022 Financial Results
November 15, 2021
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
September 20, 2021
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
September 13, 2021
Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022
September 8, 2021
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
September 8, 2021
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
September 8, 2021
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
April 27, 2021
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
April 27, 2021
Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study
February 24, 2021
Benitec Biopharma Announces 2020 Annual Stockholder Meeting
December 7, 2020
Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
October 6, 2020
Benitec Biopharma Announces Pricing of $10.0 Million Public Offering
October 2, 2020
Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results
September 23, 2020
Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference
September 1, 2020
Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study
July 8, 2020
ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States
November 27, 2019
Appendix 4C: Quarterly Cash Flow Report
October 31, 2019
Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering
September 30, 2019
Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference
September 19, 2019
ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
July 31, 2019
Update on Oculopharyngeal Muscular Dystrophy Program
June 6, 2019